Cargando…
Merck says molnupiravir has favourable benefit-risk assessment
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642203/ http://dx.doi.org/10.1007/s40278-021-06322-9 |
Ejemplares similares
-
NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021) -
Reliable SARS diagnostic only weeks away, says US CDC
Publicado: (2013) -
Tozinameran vaccination in Canada: no change in benefit-risk profile
Publicado: (2021) -
Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
Publicado: (2021) -
HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)